Lifecore Biomedical, Inc.

LFCR Healthcare Drug Manufacturers Specialty & Generic

In the quarter to June 2026, revenue fell 6.25%, EPS fell 216.7%, free cash flow fell 117.0% and total debt rose 15.3%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

6.38 0.06 −0.93%
Market cap
$244.1M
P/E
0.0×
Fwd P/E
−5.4×
Dividend yield
—
F-score
3/9
Altman Z
0.12
Beneish M
−3.15
Dividend safety
n/a

Lifecore Biomedical, Inc. (LFCR) P/E ratio

Alert me on P/E ratio

Lifecore Biomedical, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 898× (August 2019) — the current reading is the lowest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2024 14.8× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 781× 4,901.84%
FY2018 15.6× (56.34%)
FY2017 35.8× —
FY2016 0.0× —

Quarterly newest first

Period P/E ratio Change
Jun 2026 0.0× —
Mar 2026 0.0× —
Sep 2025 0.0× —
Aug 2025 0.0× —
44 more quarters

Against its own ten years

Low 0.0× High 898×
Ten-year median 0.0×
Current reading's percentile 65

P/E ratio against peers

Company P/E ratio
LFCR Lifecore Biomedical, Inc. n/m
CGC Canopy Growth Corporation compare n/m
AKBA Akebia Therapeutics, Inc. compare n/m
TKNO Alpha Teknova, Inc. compare n/m
SIGA Siga Technologies Inc. compare n/m
ACB Aurora Cannabis Inc. compare n/m
BIOA BioAge Labs, Inc. compare n/m
EBS Emergent Biosolutions Inc. compare n/m
ANIK Anika Therapeutics Inc. compare n/m
Drug Manufacturers Specialty & Generic industry median 19.2×
Healthcare sector median 23.0×
Market median 18.1×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on LFCR